Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

Not yet recruitingOBSERVATIONAL

Enrollment

800,000

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

October 30, 2024

Conditions

Cardiovascular DiseasesCardiac DiseasesVascular DiseasesCancer

Interventions

DRUG

Antineoplastic Agents

small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics

All Listed Sponsors

lead

The First Affiliated Hospital of Xinxiang Medical College

OTHER